ERβ and ApoE isoforms interact to regulate BDNF–5-HT_2A signaling and synaptic function in the female brain

go back to reference Merriam AE, et al. The psychiatric symptoms of Alzheimer’s disease. J Am Geriatr Soc. 1988;36(1):7–12.CrossRefPubMed Merriam AE, et al. The psychiatric symptoms of Alzheimer’s disease. J Am Geriatr Soc. 1988;36(1):7–12.CrossRefPubMed

go back to reference Migliorelli R, et al. Prevalence and correlates of dysthymia and major depression among patients with Alzheimer’s disease. Am J Psychiatry. 1995;152(1):37–44.CrossRefPubMed Migliorelli R, et al. Prevalence and correlates of dysthymia and major depression among patients with Alzheimer’s disease. Am J Psychiatry. 1995;152(1):37–44.CrossRefPubMed

go back to reference Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. III: Disorders of mood. Br J Psychiatry. 1990;157:81–6. 92–4.CrossRefPubMed Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. III: Disorders of mood. Br J Psychiatry. 1990;157:81–6. 92–4.CrossRefPubMed

go back to reference Starkstein SE, et al. The construct of minor and major depression in Alzheimer’s disease. Am J Psychiatry. 2005;162(11):2086–93.CrossRefPubMed Starkstein SE, et al. The construct of minor and major depression in Alzheimer’s disease. Am J Psychiatry. 2005;162(11):2086–93.CrossRefPubMed

go back to reference Suh GH, et al. Mortality in Alzheimer’s disease: a comparative prospective Korean study in the community and nursing homes. Int J Geriatr Psychiatry. 2005;20(1):26–34.CrossRefPubMed Suh GH, et al. Mortality in Alzheimer’s disease: a comparative prospective Korean study in the community and nursing homes. Int J Geriatr Psychiatry. 2005;20(1):26–34.CrossRefPubMed

go back to reference Steenland K, et al. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer’s disease in 30 US Alzheimer’s disease centers. J Alzheimers Dis. 2012;31(2):265–75.PubMedPubMedCentral Steenland K, et al. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer’s disease in 30 US Alzheimer’s disease centers. J Alzheimers Dis. 2012;31(2):265–75.PubMedPubMedCentral

go back to reference Ownby RL, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530–8.CrossRefPubMedPubMedCentral Ownby RL, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530–8.CrossRefPubMedPubMedCentral

go back to reference Diniz BS, et al. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329–35.CrossRefPubMedPubMedCentral Diniz BS, et al. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329–35.CrossRefPubMedPubMedCentral

go back to reference Gracia-Garcia P, et al. Depression and incident Alzheimer disease: the impact of disease severity. Am J Geriatr Psychiatr. 2015;23(2):119–29.CrossRef Gracia-Garcia P, et al. Depression and incident Alzheimer disease: the impact of disease severity. Am J Geriatr Psychiatr. 2015;23(2):119–29.CrossRef

go back to reference Irie F, et al. Apolipoprotein E ε4 allele genotype and the effect of depressive symptoms on the risk of dementia in men. Arch Gen Psychiatry. 2008;65(8):906–12.CrossRefPubMedPubMedCentral Irie F, et al. Apolipoprotein E ε4 allele genotype and the effect of depressive symptoms on the risk of dementia in men. Arch Gen Psychiatry. 2008;65(8):906–12.CrossRefPubMedPubMedCentral

go back to reference Wilson RS, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002;59(3):364–70.CrossRefPubMed Wilson RS, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002;59(3):364–70.CrossRefPubMed

go back to reference Wetterau JR, et al. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem. 1988;263(13):6240–8.PubMed Wetterau JR, et al. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem. 1988;263(13):6240–8.PubMed

go back to reference Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349–56.CrossRefPubMed Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349–56.CrossRefPubMed

go back to reference Huang YD, et al. Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98(15):8838–43.CrossRefPubMedPubMedCentral Huang YD, et al. Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98(15):8838–43.CrossRefPubMedPubMedCentral

go back to reference Ye SM, et al. Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A. 2005;102(51):18700–5.CrossRefPubMedPubMedCentral Ye SM, et al. Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A. 2005;102(51):18700–5.CrossRefPubMedPubMedCentral

go back to reference Roses AD. Apolipoprotein E, alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400.CrossRefPubMed Roses AD. Apolipoprotein E, alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400.CrossRefPubMed

go back to reference Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180–4.CrossRefPubMed Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180–4.CrossRefPubMed

go back to reference Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families. Science. 1993;261(5123):921–3.CrossRefPubMed Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families. Science. 1993;261(5123):921–3.CrossRefPubMed

go back to reference Myers RH, et al. Apolipoprotein E ε4 association with dementia in a population-based study: the Framingham Study. Neurology. 1996;46(3):673–7.CrossRefPubMed Myers RH, et al. Apolipoprotein E ε4 association with dementia in a population-based study: the Framingham Study. Neurology. 1996;46(3):673–7.CrossRefPubMed

go back to reference Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088–93.CrossRefPubMedPubMedCentral Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088–93.CrossRefPubMedPubMedCentral

go back to reference Jean-Charles Lambert, Simon Heath, Gael Even, Dominique Campion, Kristel Sleegers, Mikko Hiltunen, Onofre Combarros, Diana Zelenika, Maria J Bullido, Béatrice Tavernier, Luc Letenneur, Karolien Bettens, Claudine Berr, Florence Pasquier, Nathalie Fiévet, Pascale Barberger-Gateau, Sebastiaan Engelborghs, Peter De Deyn, Ignacio Mateo, Ana Franck, Seppo Helisalmi, Elisa Porcellini, Olivier Hanon, Marian M de Pancorbo, Corinne Lendon, Carole Dufouil, Céline Jaillard, Thierry Leveillard, Victoria Alvarez, Paolo Bosco, Michelangelo Mancuso, Francesco Panza, Benedetta Nacmias, Paola Bossù, Paola Piccardi, Giorgio Annoni, Davide Seripa, Daniela Galimberti, Didier Hannequin, Federico Licastro, Hilkka Soininen, Karen Ritchie, Hélène Blanché, Jean-François Dartigues, Christophe Tzourio, Ivo Gut, Christine Van Broeckhoven, Annick Alpérovitch, Mark Lathrop, Philippe Amouyel, (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics 41 (10):1094-1099 Jean-Charles Lambert, Simon Heath, Gael Even, Dominique Campion, Kristel Sleegers, Mikko Hiltunen, Onofre Combarros, Diana Zelenika, Maria J Bullido, Béatrice Tavernier, Luc Letenneur, Karolien Bettens, Claudine Berr, Florence Pasquier, Nathalie Fiévet, Pascale Barberger-Gateau, Sebastiaan Engelborghs, Peter De Deyn, Ignacio Mateo, Ana Franck, Seppo Helisalmi, Elisa Porcellini, Olivier Hanon, Marian M de Pancorbo, Corinne Lendon, Carole Dufouil, Céline Jaillard, Thierry Leveillard, Victoria Alvarez, Paolo Bosco, Michelangelo Mancuso, Francesco Panza, Benedetta Nacmias, Paola Bossù, Paola Piccardi, Giorgio Annoni, Davide Seripa, Daniela Galimberti, Didier Hannequin, Federico Licastro, Hilkka Soininen, Karen Ritchie, Hélène Blanché, Jean-François Dartigues, Christophe Tzourio, Ivo Gut, Christine Van Broeckhoven, Annick Alpérovitch, Mark Lathrop, Philippe Amouyel, (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics 41 (10):1094-1099

go back to reference Sudha Seshadri, (2010) Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease. JAMA 303 (18):1832 Sudha Seshadri, (2010) Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease. JAMA 303 (18):1832

go back to reference Butters MA, et al. APOE is associated with age-of-onset, but not cognition, in late-life depression. Int J Geriatr Psychiatry. 2003;18(12):1075–81.CrossRefPubMed Butters MA, et al. APOE is associated with age-of-onset, but not cognition, in late-life depression. Int J Geriatr Psychiatry. 2003;18(12):1075–81.CrossRefPubMed

go back to reference Rigaud AS, et al. Association of the apolipoprotein E ε4 allele with late-onset depression. Neuroepidemiology. 2001;20(4):268–72.CrossRefPubMed Rigaud AS, et al. Association of the apolipoprotein E ε4 allele with late-onset depression. Neuroepidemiology. 2001;20(4):268–72.CrossRefPubMed

go back to reference Skoog I, et al. A 9-year prospective population-based study on the association between the APOE*E4 allele and late-life depression in Sweden. Biol Psychiatry. 2015;78(10):730–6.CrossRefPubMed Skoog I, et al. A 9-year prospective population-based study on the association between the APOE*E4 allele and late-life depression in Sweden. Biol Psychiatry. 2015;78(10):730–6.CrossRefPubMed

go back to reference Sureshkumar R, et al. ApoE4 and late onset depression in Indian population. J Affect Disord. 2012;136(3):244–8.CrossRefPubMed Sureshkumar R, et al. ApoE4 and late onset depression in Indian population. J Affect Disord. 2012;136(3):244–8.CrossRefPubMed

go back to reference Fan PL, et al. Protective effect of the apo epsilon 2 allele in major depressive disorder in Taiwanese. Acta Psychiatr Scand. 2006;113(1):48–53.CrossRefPubMed Fan PL, et al. Protective effect of the apo epsilon 2 allele in major depressive disorder in Taiwanese. Acta Psychiatr Scand. 2006;113(1):48–53.CrossRefPubMed

go back to reference Julian LJ, et al. ApoE alleles, depression and positive affect in multiple sclerosis. Mult Scler. 2009;15(3):311–5.CrossRefPubMedPubMedCentral Julian LJ, et al. ApoE alleles, depression and positive affect in multiple sclerosis. Mult Scler. 2009;15(3):311–5.CrossRefPubMedPubMedCentral

go back to reference Chhibber A, et al. Estrogen receptor β deficiency impairs BDNF-5-HT2A signaling in the hippocampus of female brain: a possible mechanism for menopausal depression. Psychoneuroendocrinology. 2017;82:107–16.CrossRefPubMed Chhibber A, et al. Estrogen receptor β deficiency impairs BDNF-5-HT2A signaling in the hippocampus of female brain: a possible mechanism for menopausal depression. Psychoneuroendocrinology. 2017;82:107–16.CrossRefPubMed

go back to reference Knouff C, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103(11):1579–86.CrossRefPubMedPubMedCentral Knouff C, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103(11):1579–86.CrossRefPubMedPubMedCentral

go back to reference Sullivan PM, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272(29):17972–80.CrossRefPubMed Sullivan PM, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272(29):17972–80.CrossRefPubMed

go back to reference Zhao L, Mao Z, Brinton RD. A select combination of clinically relevant phytoestrogens enhances estrogen receptor β-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology. 2009;150(2):770–83.CrossRefPubMed Zhao L, Mao Z, Brinton RD. A select combination of clinically relevant phytoestrogens enhances estrogen receptor β-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology. 2009;150(2):770–83.CrossRefPubMed

go back to reference Zhao L, et al. Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause. 2011;18(10):1131–42.CrossRefPubMed Zhao L, et al. Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause. 2011;18(10):1131–42.CrossRefPubMed

go back to reference Zhao L, et al. Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer’s disease. J Alzheimers Dis. 2013;37(2):403–19.PubMedPubMedCentral Zhao L, et al. Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer’s disease. J Alzheimers Dis. 2013;37(2):403–19.PubMedPubMedCentral

go back to reference Nautiyal KM, Hen R. Serotonin receptors in depression: from A to B. F1000Res. 2017;6:123.CrossRefPubMedPubMedCentral Nautiyal KM, Hen R. Serotonin receptors in depression: from A to B. F1000Res. 2017;6:123.CrossRefPubMedPubMedCentral

go back to reference Celada P, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252–65.PubMedPubMedCentral Celada P, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252–65.PubMedPubMedCentral

go back to reference Christopher Pittenger, Ronald S Duman, (2007) Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms. Neuropsychopharmacology 33 (1):88-109 Christopher Pittenger, Ronald S Duman, (2007) Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms. Neuropsychopharmacology 33 (1):88-109

go back to reference Linnea Vose, Patric Stanton, (2016) Synaptic Plasticity, Metaplasticity and Depression. Current Neuropharmacology 15 (1):71-86 Linnea Vose, Patric Stanton, (2016) Synaptic Plasticity, Metaplasticity and Depression. Current Neuropharmacology 15 (1):71-86

go back to reference Pandey GN, et al. Higher expression of serotonin 5-HT2A receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry. 2002;159(3):419–29.CrossRefPubMed Pandey GN, et al. Higher expression of serotonin 5-HT_2A receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry. 2002;159(3):419–29.CrossRefPubMed

go back to reference Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29(8):1512–21.CrossRefPubMed Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29(8):1512–21.CrossRefPubMed

go back to reference Shelton RC, et al. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience. 2009;158(4):1406–15.CrossRefPubMed Shelton RC, et al. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience. 2009;158(4):1406–15.CrossRefPubMed

go back to reference Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116–27.CrossRefPubMed Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116–27.CrossRefPubMed

go back to reference Dwivedi Y, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60(8):804–15.CrossRefPubMed Dwivedi Y, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60(8):804–15.CrossRefPubMed

go back to reference Tannenberg RK, et al. Selective loss of synaptic proteins in Alzheimer’s disease: evidence for an increased severity with APOE varepsilon4. Neurochem Int. 2006;49(7):631–9.CrossRefPubMed Tannenberg RK, et al. Selective loss of synaptic proteins in Alzheimer’s disease: evidence for an increased severity with APOE varepsilon4. Neurochem Int. 2006;49(7):631–9.CrossRefPubMed

go back to reference Zhu Y, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia. 2012;60(4):559–69.CrossRefPubMedPubMedCentral Zhu Y, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia. 2012;60(4):559–69.CrossRefPubMedPubMedCentral

go back to reference Ji Y, et al. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer’s disease patients. Neuroscience. 2003;122(2):305–15.CrossRefPubMed Ji Y, et al. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer’s disease patients. Neuroscience. 2003;122(2):305–15.CrossRefPubMed

go back to reference Dumanis SB, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29(48):15317–22.CrossRefPubMedPubMedCentral Dumanis SB, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29(48):15317–22.CrossRefPubMedPubMedCentral

go back to reference Struble RG, et al. Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front Biosci. 2008;13:5387–405.CrossRefPubMed Struble RG, et al. Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front Biosci. 2008;13:5387–405.CrossRefPubMed

go back to reference Yaffe K, et al. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology. 2000;54(10):1949–54.CrossRefPubMed Yaffe K, et al. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology. 2000;54(10):1949–54.CrossRefPubMed

go back to reference Nathan BP, et al. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology. 2004;145(7):3065–73.CrossRefPubMed Nathan BP, et al. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology. 2004;145(7):3065–73.CrossRefPubMed

go back to reference Kunzler J, et al. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice. Neurosci Lett. 2014;560:131–6.CrossRefPubMed Kunzler J, et al. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice. Neurosci Lett. 2014;560:131–6.CrossRefPubMed

go back to reference Burkhardt MS, et al. Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis. 2004;6(3):221–8.CrossRefPubMed Burkhardt MS, et al. Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis. 2004;6(3):221–8.CrossRefPubMed

go back to reference Jacobs EG, et al. Accelerated cell aging in female APOE-epsilon4 carriers: implications for hormone therapy use. PLoS One. 2013;8(2):e54713.CrossRefPubMedPubMedCentral Jacobs EG, et al. Accelerated cell aging in female APOE-epsilon4 carriers: implications for hormone therapy use. PLoS One. 2013;8(2):e54713.CrossRefPubMedPubMedCentral

go back to reference Ryan J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology. 2009;73(21):1729–37.CrossRefPubMedPubMedCentral Ryan J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology. 2009;73(21):1729–37.CrossRefPubMedPubMedCentral

go back to reference Yue Y, et al. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. Acta Pharmacol Sin. 2007;28(8):1129–35.CrossRefPubMed Yue Y, et al. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. Acta Pharmacol Sin. 2007;28(8):1129–35.CrossRefPubMed

go back to reference Carranza-Lira S, Valentino-Figueroa ML. Estrogen therapy for depression in postmenopausal women. Int J Gynaecol Obstet. 1999;65(1):35–8.CrossRefPubMed Carranza-Lira S, Valentino-Figueroa ML. Estrogen therapy for depression in postmenopausal women. Int J Gynaecol Obstet. 1999;65(1):35–8.CrossRefPubMed

go back to reference Soares CN, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529–34.CrossRefPubMed Soares CN, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529–34.CrossRefPubMed

go back to reference Rasgon NL, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63 Suppl 7:45–8.PubMed Rasgon NL, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63 Suppl 7:45–8.PubMed

go back to reference Yang F, et al. Estradiol decreases rat depressive behavior by estrogen receptor β but not alpha: no correlation with plasma corticosterone. Neuroreport. 2014;25(2):100–4.CrossRefPubMed Yang F, et al. Estradiol decreases rat depressive behavior by estrogen receptor β but not alpha: no correlation with plasma corticosterone. Neuroreport. 2014;25(2):100–4.CrossRefPubMed

go back to reference Weiser MJ, Wu TJ, Handa RJ. Estrogen receptor-β agonist diarylpropionitrile: biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology. 2009;150(4):1817–25.CrossRefPubMed Weiser MJ, Wu TJ, Handa RJ. Estrogen receptor-β agonist diarylpropionitrile: biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology. 2009;150(4):1817–25.CrossRefPubMed

go back to reference Walf AA, Koonce CJ, Frye CA. Adult female wildtype, but not oestrogen receptor β knockout, mice have decreased depression-like behaviour during pro-oestrus and following administration of oestradiol or diarylpropionitrile. J Psychopharmacol. 2009;23(4):442–50.CrossRefPubMed Walf AA, Koonce CJ, Frye CA. Adult female wildtype, but not oestrogen receptor β knockout, mice have decreased depression-like behaviour during pro-oestrus and following administration of oestradiol or diarylpropionitrile. J Psychopharmacol. 2009;23(4):442–50.CrossRefPubMed

go back to reference Singh RK, et al. Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J Pharmacol Exp Ther. 2007;322(1):133–40.CrossRefPubMed Singh RK, et al. Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J Pharmacol Exp Ther. 2007;322(1):133–40.CrossRefPubMed